Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.

Identifieur interne : 001930 ( Main/Exploration ); précédent : 001929; suivant : 001931

Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.

Auteurs : Tao Ren [République populaire de Chine] ; Zhen-Ke Wen ; Zhong-Min Liu ; Cheng Qian ; Yong-Jie Liang ; Mei-Ling Jin ; Ying-Yun Cai ; Lin Xu

Source :

RBID : pubmed:18568766

Descripteurs français

English descriptors

Abstract

CpG-oligonucleotides (CpG-ODN), which induce signaling through Toll-like receptor 9 (TLR9), are currently under investigation as adjuvants in therapy against infections and cancer. However, whether the CpG-ODN alone could enhance the anti-tumor immunity and the underlying mechanisms remains unclear. Here, we investigated that stimulation of peripheral blood mononuclear cells (PBMCs) from human lung cancer patients with CpG-ODN induced proliferation responses of the PBMCs, accompanied by the elevated cytokine secretion, including IFN-alpha, IL-12 and TNF-alpha. In addition, after treatment with CpG-ODN, the cytotoxic activity of the PBMCs and the production of IFN-gamma in CD8(+) T cells were dramatically enhanced. Furthermore, we found that adoptive transfer of CpG-ODN treated PBMCs significantly inhibited the tumor progression in nude mice, which were challenged with the autologuous tumor cells from human lung cancer patients. Finally, we demonstrated that the inhibitory CpG ODN or chloroquine could dramatically abrogate the enhanced anti-tumor responses of the CpG ODN treated PBMCs. Our findings suggest that the CpG-ODN is promising as a preventive and therapeutic anti-tumor measure against pulmonary carcinoma.

DOI: 10.1080/07357900701681608
PubMed: 18568766


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.</title>
<author>
<name sortKey="Ren, Tao" sort="Ren, Tao" uniqKey="Ren T" first="Tao" last="Ren">Tao Ren</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Respiratory Medicine, East Hospital, Tongji University, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Respiratory Medicine, East Hospital, Tongji University, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Wen, Zhen Ke" sort="Wen, Zhen Ke" uniqKey="Wen Z" first="Zhen-Ke" last="Wen">Zhen-Ke Wen</name>
</author>
<author>
<name sortKey="Liu, Zhong Min" sort="Liu, Zhong Min" uniqKey="Liu Z" first="Zhong-Min" last="Liu">Zhong-Min Liu</name>
</author>
<author>
<name sortKey="Qian, Cheng" sort="Qian, Cheng" uniqKey="Qian C" first="Cheng" last="Qian">Cheng Qian</name>
</author>
<author>
<name sortKey="Liang, Yong Jie" sort="Liang, Yong Jie" uniqKey="Liang Y" first="Yong-Jie" last="Liang">Yong-Jie Liang</name>
</author>
<author>
<name sortKey="Jin, Mei Ling" sort="Jin, Mei Ling" uniqKey="Jin M" first="Mei-Ling" last="Jin">Mei-Ling Jin</name>
</author>
<author>
<name sortKey="Cai, Ying Yun" sort="Cai, Ying Yun" uniqKey="Cai Y" first="Ying-Yun" last="Cai">Ying-Yun Cai</name>
</author>
<author>
<name sortKey="Xu, Lin" sort="Xu, Lin" uniqKey="Xu L" first="Lin" last="Xu">Lin Xu</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18568766</idno>
<idno type="pmid">18568766</idno>
<idno type="doi">10.1080/07357900701681608</idno>
<idno type="wicri:Area/PubMed/Corpus">000415</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000415</idno>
<idno type="wicri:Area/PubMed/Curation">000415</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000415</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000402</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000402</idno>
<idno type="wicri:Area/Ncbi/Merge">000112</idno>
<idno type="wicri:Area/Ncbi/Curation">000112</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000112</idno>
<idno type="wicri:Area/Main/Merge">001936</idno>
<idno type="wicri:Area/Main/Curation">001930</idno>
<idno type="wicri:Area/Main/Exploration">001930</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.</title>
<author>
<name sortKey="Ren, Tao" sort="Ren, Tao" uniqKey="Ren T" first="Tao" last="Ren">Tao Ren</name>
<affiliation wicri:level="1">
<nlm:affiliation>Department of Respiratory Medicine, East Hospital, Tongji University, Shanghai, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Respiratory Medicine, East Hospital, Tongji University, Shanghai</wicri:regionArea>
<wicri:noRegion>Shanghai</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Wen, Zhen Ke" sort="Wen, Zhen Ke" uniqKey="Wen Z" first="Zhen-Ke" last="Wen">Zhen-Ke Wen</name>
</author>
<author>
<name sortKey="Liu, Zhong Min" sort="Liu, Zhong Min" uniqKey="Liu Z" first="Zhong-Min" last="Liu">Zhong-Min Liu</name>
</author>
<author>
<name sortKey="Qian, Cheng" sort="Qian, Cheng" uniqKey="Qian C" first="Cheng" last="Qian">Cheng Qian</name>
</author>
<author>
<name sortKey="Liang, Yong Jie" sort="Liang, Yong Jie" uniqKey="Liang Y" first="Yong-Jie" last="Liang">Yong-Jie Liang</name>
</author>
<author>
<name sortKey="Jin, Mei Ling" sort="Jin, Mei Ling" uniqKey="Jin M" first="Mei-Ling" last="Jin">Mei-Ling Jin</name>
</author>
<author>
<name sortKey="Cai, Ying Yun" sort="Cai, Ying Yun" uniqKey="Cai Y" first="Ying-Yun" last="Cai">Ying-Yun Cai</name>
</author>
<author>
<name sortKey="Xu, Lin" sort="Xu, Lin" uniqKey="Xu L" first="Lin" last="Xu">Lin Xu</name>
</author>
</analytic>
<series>
<title level="j">Cancer investigation</title>
<idno type="eISSN">1532-4192</idno>
<imprint>
<date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adjuvants, Immunologic (pharmacology)</term>
<term>Animals</term>
<term>Antineoplastic Agents (pharmacology)</term>
<term>CD8-Positive T-Lymphocytes (drug effects)</term>
<term>CD8-Positive T-Lymphocytes (immunology)</term>
<term>Cell Proliferation (drug effects)</term>
<term>Cells, Cultured</term>
<term>Chloroquine (pharmacology)</term>
<term>Cytotoxicity, Immunologic (drug effects)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Humans</term>
<term>Immunotherapy (methods)</term>
<term>Immunotherapy, Adoptive</term>
<term>Interferon-alpha (metabolism)</term>
<term>Interleukin-12 (metabolism)</term>
<term>Leukocytes, Mononuclear (drug effects)</term>
<term>Leukocytes, Mononuclear (immunology)</term>
<term>Leukocytes, Mononuclear (transplantation)</term>
<term>Lung Neoplasms (immunology)</term>
<term>Lung Neoplasms (therapy)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Mice, Nude</term>
<term>Oligodeoxyribonucleotides (pharmacology)</term>
<term>Time Factors</term>
<term>Toll-Like Receptor 9 (metabolism)</term>
<term>Tumor Cells, Cultured</term>
<term>Tumor Necrosis Factor-alpha (metabolism)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adjuvants immunologiques (pharmacologie)</term>
<term>Agranulocytes ()</term>
<term>Agranulocytes (immunologie)</term>
<term>Agranulocytes (transplantation)</term>
<term>Animaux</term>
<term>Antinéoplasiques (pharmacologie)</term>
<term>Cellules cancéreuses en culture</term>
<term>Cellules cultivées</term>
<term>Chloroquine (pharmacologie)</term>
<term>Cytotoxicité immunologique ()</term>
<term>Facteur de nécrose tumorale alpha (métabolisme)</term>
<term>Facteurs temps</term>
<term>Humains</term>
<term>Immunothérapie ()</term>
<term>Immunothérapie adoptive</term>
<term>Interféron alpha (métabolisme)</term>
<term>Interleukine-12 (métabolisme)</term>
<term>Lymphocytes T CD8+ ()</term>
<term>Lymphocytes T CD8+ (immunologie)</term>
<term>Oligodésoxyribonucléotides (pharmacologie)</term>
<term>Prolifération cellulaire ()</term>
<term>Relation dose-effet des médicaments</term>
<term>Récepteur-9 de type Toll-like (métabolisme)</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Souris nude</term>
<term>Tumeurs du poumon ()</term>
<term>Tumeurs du poumon (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Interferon-alpha</term>
<term>Interleukin-12</term>
<term>Toll-Like Receptor 9</term>
<term>Tumor Necrosis Factor-alpha</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Adjuvants, Immunologic</term>
<term>Antineoplastic Agents</term>
<term>Chloroquine</term>
<term>Oligodeoxyribonucleotides</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>CD8-Positive T-Lymphocytes</term>
<term>Cell Proliferation</term>
<term>Cytotoxicity, Immunologic</term>
<term>Leukocytes, Mononuclear</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr">
<term>Agranulocytes</term>
<term>Lymphocytes T CD8+</term>
<term>Tumeurs du poumon</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en">
<term>CD8-Positive T-Lymphocytes</term>
<term>Leukocytes, Mononuclear</term>
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en">
<term>Immunotherapy</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Facteur de nécrose tumorale alpha</term>
<term>Interféron alpha</term>
<term>Interleukine-12</term>
<term>Récepteur-9 de type Toll-like</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Adjuvants immunologiques</term>
<term>Antinéoplasiques</term>
<term>Chloroquine</term>
<term>Oligodésoxyribonucléotides</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en">
<term>Lung Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="transplantation" xml:lang="en">
<term>Leukocytes, Mononuclear</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Cells, Cultured</term>
<term>Dose-Response Relationship, Drug</term>
<term>Humans</term>
<term>Immunotherapy, Adoptive</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Mice, Nude</term>
<term>Time Factors</term>
<term>Tumor Cells, Cultured</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Agranulocytes</term>
<term>Animaux</term>
<term>Cellules cancéreuses en culture</term>
<term>Cellules cultivées</term>
<term>Cytotoxicité immunologique</term>
<term>Facteurs temps</term>
<term>Humains</term>
<term>Immunothérapie</term>
<term>Immunothérapie adoptive</term>
<term>Lymphocytes T CD8+</term>
<term>Prolifération cellulaire</term>
<term>Relation dose-effet des médicaments</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Souris nude</term>
<term>Tumeurs du poumon</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">CpG-oligonucleotides (CpG-ODN), which induce signaling through Toll-like receptor 9 (TLR9), are currently under investigation as adjuvants in therapy against infections and cancer. However, whether the CpG-ODN alone could enhance the anti-tumor immunity and the underlying mechanisms remains unclear. Here, we investigated that stimulation of peripheral blood mononuclear cells (PBMCs) from human lung cancer patients with CpG-ODN induced proliferation responses of the PBMCs, accompanied by the elevated cytokine secretion, including IFN-alpha, IL-12 and TNF-alpha. In addition, after treatment with CpG-ODN, the cytotoxic activity of the PBMCs and the production of IFN-gamma in CD8(+) T cells were dramatically enhanced. Furthermore, we found that adoptive transfer of CpG-ODN treated PBMCs significantly inhibited the tumor progression in nude mice, which were challenged with the autologuous tumor cells from human lung cancer patients. Finally, we demonstrated that the inhibitory CpG ODN or chloroquine could dramatically abrogate the enhanced anti-tumor responses of the CpG ODN treated PBMCs. Our findings suggest that the CpG-ODN is promising as a preventive and therapeutic anti-tumor measure against pulmonary carcinoma.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>République populaire de Chine</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Cai, Ying Yun" sort="Cai, Ying Yun" uniqKey="Cai Y" first="Ying-Yun" last="Cai">Ying-Yun Cai</name>
<name sortKey="Jin, Mei Ling" sort="Jin, Mei Ling" uniqKey="Jin M" first="Mei-Ling" last="Jin">Mei-Ling Jin</name>
<name sortKey="Liang, Yong Jie" sort="Liang, Yong Jie" uniqKey="Liang Y" first="Yong-Jie" last="Liang">Yong-Jie Liang</name>
<name sortKey="Liu, Zhong Min" sort="Liu, Zhong Min" uniqKey="Liu Z" first="Zhong-Min" last="Liu">Zhong-Min Liu</name>
<name sortKey="Qian, Cheng" sort="Qian, Cheng" uniqKey="Qian C" first="Cheng" last="Qian">Cheng Qian</name>
<name sortKey="Wen, Zhen Ke" sort="Wen, Zhen Ke" uniqKey="Wen Z" first="Zhen-Ke" last="Wen">Zhen-Ke Wen</name>
<name sortKey="Xu, Lin" sort="Xu, Lin" uniqKey="Xu L" first="Lin" last="Xu">Lin Xu</name>
</noCountry>
<country name="République populaire de Chine">
<noRegion>
<name sortKey="Ren, Tao" sort="Ren, Tao" uniqKey="Ren T" first="Tao" last="Ren">Tao Ren</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001930 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001930 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:18568766
   |texte=   Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:18568766" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021